Weitz & Luxenberg is taking legal cases for patients who have cutaneous T-cell lymphoma (CTCL) and used an anti-inflammatory medication. Reach out to us if you have been diagnosed with this type of skin cancer, so we can help you get the financial compensation you deserve.
Dupixent (dupilumab) is prescribed to patients diagnosed with moderate to severe atopic dermatitis (AD), among other medical conditions.
Cutaneous T-cell lymphoma is a type of skin cancer that develops in white blood cells called T-lymphocytes. White blood cells are part of your immune system. They fight infection. T-cell lymphoma can develop anywhere in your body where there is lymph tissue. (1)
Signs and Symptoms of Cutaneous T-Cell Lymphoma
Signs of CTCL include scaly patches or bumps on your skin that are dry and red. Symptoms can include rashes, lumps and tumors, discoloration, thickened skin, swollen lymph nodes, hair loss, itching, fever and chills, unexplained weight loss, pain or tenderness, and night sweats. (2)
As CTCL progresses, the visual changes to your skin can cover up to 80% of your skin’s surface. As the disease worsens, CTCL can spread to your internal organs, including your spleen and liver. (3)
Drug Companies Did Not Warn Patients of Cancer Risk
Regeneron Pharmaceuticals and Sanofi Genzyme failed to adequately warn of the risks in taking Dupixent. And our Weitz & Luxenberg team is taking action.
“Cutaneous T-cell lymphoma is a very rare type of skin cancer. This makes it all the more critical for the manufacturer to warn patients about the danger,” states Ellen Relkin, W&L partner and practice group chair of our Drug and Medical Device Litigation team.
“Doctors and patients alike need to be sufficiently warned. And patients who take Dupixent, and their doctors, need to keep a careful eye out for any disturbing changes to their skin,” says Ms. Relkin.
“Those who took Dupixent and are suffering deserve compensation. And we are going to help you get it,” she insists.
Have CTCL and used Dupixent? Contact Weitz & Luxenberg to find out if you qualify for a lawsuit.
Get Your Free Case Evaluation TodayDupixent Is Used to Treat Allergic Diseases
Dupixent is used to treat allergic diseases. Dupilumab injections are meant to stop certain substances in your body that cause inflammation. (4)
In addition to atopic dermatitis (eczema), this includes asthma, and nasal polyps that lead to chronic sinusitis. Dupixent is also used to treat eosinophilic esophagitis, prurigo nodularis, and chronic obstructive pulmonary disease (COPD).
Dupixent is a monoclonal antibody developed by Regeneron Pharmaceuticals and Sanofi Genzyme. The drug was released in 2017. Dupilumab targets your interleukin 4 alpha receptor. (5)
Research Suggests Dupixent Can Lead to CTCL
Research reports link the use of dupilumab, the active ingredient in Dupixent, with CTCL. Dupilumab may exacerbate pre-existing CTCL or increase your susceptibility of developing it. (6)
A study in the Journal of the American Academy of Dermatology reported an increased risk of CTCL was found in a cohort of atopic dermatitis patients who used dupilumab. “The increased risk persisted after exclusion of prior disease-modifying antirheumatic drug use. Risk was not increased for other cutaneous or lymphoid malignancies.” (7)
Medical researchers advise “diligent monitoring” of patients who have been treated with dupilumab. “At the first sign” of an adverse reaction, doctors should examine their patients very carefully for signs of CTCL. (8)
Getting Compensation for Dupixent-Related Skin Cancer
Weitz & Luxenberg is currently accepting cases of people who have skin cancer and took Dupixent. You may be entitled to compensation if you took Dupixent and have cutaneous T-cell lymphoma (CTCL).
To qualify for compensation, you need to have been diagnosed with CTCL or one of its subtypes and used the drug for at least one month. You also need to show that you were not diagnosed with Hodgkin lymphoma, non-Hodgkin lymphoma, non-follicular lymphoma, or leukemia before receiving your first dose of Dupixent.
CTCL Illnesses Due to Dupixent Use that May Qualify for Compensation
We are filing suit against the manufacturer of Dupixent on behalf of patients who developed CTCL. Other names for CTCL are mycosis fungoides and Sézary syndrome.
Less common types of CTCL are lymphomatoid papulosis, subcutaneous panniculitis-like T-cell lymphoma, primary cutaneous anaplastic large cell lymphoma, extranodal NK/T-cell lymphoma, and primary cutaneous gamma/delta T-cell lymphoma.
W&L Helping People Who Have Skin Cancer and Used Dupixent
Weitz & Luxenberg is encouraging anyone diagnosed with CTCL who used Dupixent to contact us for information about your legal options. You may use the online form on this page or call (917) LAWYERS. Your initial consultation is free.
W&L has secured more than $19 billion in settlements and verdicts on behalf of people injured by the irresponsible actions of large corporations. We have represented tens of thousands of clients over the years.
Our experienced attorneys who handle defective drugs and devices can help you consider your legal options. Reach out to us now to get help.
